Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy.

JCO Precis Oncol · 2018 · PMC6040635 · PMID 30088816

Europe PMC DOI

hedged sentences

0.0880

closest p · 1.8× alpha

0.0890

boldest claim

The sentences

failed to reach significanceP = .088so close (0.05 < p ≤ 0.1)

There was also significant benefit from adjuvant chemotherapy in the stage III CMS3 subtype (log-rank test P = .001; HR, 0.16 [Wald test P = 2.95 × 10 −3 ]; Data Supplement) and a trend for benefit from chemotherapy in the stage II CMS3 subtype; however, this failed to reach significance (log-rank test P = .088; Data Supplement).

also in 4,113 other papers

a nonsignificant trendP = .089so close (0.05 < p ≤ 0.1)

Of note, no significant benefit from adjuvant chemotherapy was observed in CMS1 or CMS4, although a nonsignificant trend was observed in CMS4 stage III disease (log-rank test P = .089; Data Supplement).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.